The Food and Drug Administration announced on Monday it has given full approval for a new preventative injection for infants under age 2 to protect them from contracting respiratory syncytial virus, ...

After a large-scale exposure, health department developed a protocol for statewide use ...

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an ...

Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is uncertain. In this phase 3, ...